Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

Jose Baselga, Ian Bradbury, Holger Eidtmann, Serena Di Cosimo, Evandro de Azambuja, Claudia Aura, Henry Gomez, Phuong Dinh, Karine Kauria, Veerie Van Dooren, Gursel Aktan, Aron Goldhirsch, Tsai-Wang Chang, Zsolt Horvath, Maria Coccia-Portugal, Julien Domont, Ling-Min Tseng, Georg Gunz, Joo Hyuk Sohn, Vladimir SemiglazovGuillermo Lerzo, Marketa Palacova, Volodymur Probachai, Lajos Pusztai

    Research output: Contribution to journalArticle

    877 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)663-640
    JournalThe Lancet
    Volume379
    Issue number9816
    DOIs
    Publication statusPublished - 2012

    Cite this

    Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., de Azambuja, E., Aura, C., Gomez, H., Dinh, P., Kauria, K., Van Dooren, V., Aktan, G., Goldhirsch, A., Chang, T-W., Horvath, Z., Coccia-Portugal, M., Domont, J., Tseng, L-M., Gunz, G., Hyuk Sohn, J., ... Pusztai, L. (2012). Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. The Lancet, 379(9816), 663-640. https://doi.org/10.1016/S0140-6736(11)61847-3